Clinical Trials
134
Active:2
Completed:9
Trial Phases
6 Phases
Early Phase 1:3
Phase 1:10
Phase 2:67
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (117 trials with phase data)• Click on a phase to view related trials
Phase 2
67 (57.3%)Not Applicable
23 (19.7%)Phase 3
13 (11.1%)Phase 1
10 (8.5%)Early Phase 1
3 (2.6%)Phase 4
1 (0.9%)Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal
Not Applicable
Not yet recruiting
- Conditions
- Small-Cell Carcinoma of the Esophageal
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT07155122
Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
Not Applicable
Recruiting
- Conditions
- Gastric Cancer
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT07142122
- Locations
- 🇨🇳
420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province, Fuzhou, Fujian, China
A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors
Not Applicable
Active, not recruiting
- Conditions
- Colorectal CancerGastric Cancer (GC)Gastrointestinal Tumors
- Interventions
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT07104877
- Locations
- 🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Not Applicable
Not yet recruiting
- Conditions
- Early Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer
- Interventions
- Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT07101159
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
Not yet recruiting
- Conditions
- Recurrent Nasopharyngeal Carcinoma
- Interventions
- Drug: ICI-chemotherapy and LIMT
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT07088484
- Prev
- 1
- 2
- 3
- 4
- 5
- 27
- Next
News
No news found